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The Association Between Low  
Back Pain and Composition  
of IgG Glycome
Maxim B. Freidin1,*, Toma Keser2,*, Ivan Gudelj3, Jerko Štambuk3, Dunja Vučenović1,4, 
Massimo Allegri5, Tamara Pavić2, Mirna Šimurina2, Stella M. Fabiane1, Gordan Lauc2,3,# & 
Frances M. K. Williams1,#
Low back pain (LBP) is a common debilitating condition which aetiology and pathogenesis are 
poorly understood. We carried out a first so far analysis of associations between LBP and plasma 
IgG N-glycome in a sample of 4511 twins from TwinsUK database assessed for LBP, lumbar disc 
degeneration (LDD) as its possible cause, and IgG-glycan levels. Using weighted correlation network 
analysis, we established a correlation between LBP and glycan modules featured by glycans that either 
promote or block antibody-dependent cell-mediated cytotoxicity (ADCC). The levels of four glycan 
traits representing two of those modules were statistically significantly different in monozygotic 
twins discordant for LBP. Also, the trend to higher prevalence of systemic inflammatory disorders was 
shown for twins with low level of fucosylated glycans and high level of non-fucosylated glycans. Core 
fucosylation of IgG is a “safety switch” reducing ADCC, thus our results suggest the involvement of 
ADCC and associated inflammation in pathogenesis of LBP. No correlation between LDD scores and 
glycans was found assuming that the inflammation may not be a part of LDD. These data provide a new 
insight into understanding the complex pathophysiology of LBP and suggest glycan levels as a possible 
biomarker for inflammation-related subtypes of LBP.
Low back pain (LBP) is a common musculoskeletal condition in all ages1. The lifetime prevalence of non-specific 
LBP may reach 80%, with the annual prevalence ranging between 25% and 60% in different ethnic groups2,3. It is a 
diverse group of mixed pain syndromes with different molecular pathologies at different structural levels display-
ing similar clinical manifestations and radiologic findings. Why there is such huge inter-personal variability in 
severity of chronic LBP is yet to be clearly defined. Lumbar disk degeneration (LDD) is widely believed to be one 
of the major contributing factors. Nevertheless, MRI findings of disc degeneration cannot help to define clearly 
the pathophysiology of LBP and its prognosis4.
Even though, the development of LDD is associated with such occupational factors as heavy lifting, frequent 
bending and twisting5, genetic predisposition is much more important as a risk factor6.
A TwinsUK study showed genetic background as the major factor associated with LBP in women and also 
revealed a significant genetic correlation between LBP and LDD7. Genetic studies identified a dozen of genes 
associated with LDD, such as genes coding collagens, vitamin D receptor, interleukins, matrix metalloproteinases 
and other molecules8,9.
Large genome-wide linkage study and a genome-wide meta-analysis identified CHST3 gene associated with 
LDD, and a subsequent functional analysis showed the risk allele decreases the gene expression, possibly, due to 
the enhanced interaction with miR-513a-5p microRNA10. Also, a meta-analysis of several genome-wide associa-
tion studies revealed an association between LDD and PARK gene with the differential methylation of the PARK 
gene promoter as a possible cause for the association11. Also, an increased methylation of SPARC gene was found 
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to be associated with LBP and LDD in humans and mice12. These studies incur epigenetic factors in the develop-
ment of LDD and LBP.
Thus, the discovery of molecular factors contributing to the predisposition to LBP and LDD and mechanisms 
by which these factors act is essential to facilitate the development of new biomarkers of risk and response to 
specific treatments. Apart from genomic and epigenomic factors, other newly established “omes” can be of value.
In particular, glycome (the entire composition of glycans) attracts attention. Glycans constitute the most abun-
dant and diverse form of the post-translational modifications. All cell surface and secreted glycoproteins that 
contain appropriate sequences (Asn-X-Ser/Thr where X is any amino acid except proline) can potentially acquire 
N-linked oligosaccharides (N-glycans) while they travel through the endoplasmic reticulum and the Golgi com-
partments. Glycans can influence disease development in many syndromes such as congenital disorders of glyco-
sylation, cancer, rheumatoid arthritis and AIDS13. Glycans are crucial for the immune system, as some of the most 
important interactions between the immune system and viruses and bacteria are mediated by protein-glycan 
interactions. The biological functions of glycans go from basic structural roles to development, protein folding 
and immune response.
While genes unequivocally determine the structure of each polypeptide, there is no genetic template for the 
glycan part. Instead, hundreds of genes and their products interact in the complex pathway of glycan biosynthesis 
resulting in a very complex biosynthetic pathway that is further complicated by both direct environmental influence 
(nutrition, hormonal status, etc) and epigenetic memory of past environmental effects (altered gene expression)14–16. 
It is possible that some of the considerable genetic predisposition to LDD may be mediated via glycans.
Immunoglobulin G (IgG) glycosylation has been well defined, and many important functional effects of 
alternative IgG glycosylation have been described17. Glycans that lack terminal galactose activate complement 
and make IgG pro-inflammatory, while the addition of galactose decreases inflammatory potential of IgG18,19. 
Further extension of IgG glycans by the addition of sialic acid dramatically changes the physiological role of 
IgG, converting it from a pro-inflammatory into an anti-inflammatory agent. Terminal α2,6-sialylation of IgG 
glycans decreases the ability of IgG to bind to activating FcγRs and promotes recognition by DC-SIGN, which 
increases expression of inhibitory FcγRIIB and is anti-inflammatory20. Another example is the role of core fucose 
in the modulation of antibody-dependent cellular cytotoxicity: IgG-containing glycans that lack core fucose have 
100-fold increased affinity for FcγRIIIA and are therefore much more efficient in activating antibody-dependent 
cellular cytotoxicity than fucosylated glycoforms of the same molecule21.
In this study, we analyzed twins from TwinsUK registry, to assess whether persons reporting episodes of LBP 
had detectable levels of altered IgG glycosylation.
Results
The study aimed at identifying relationships between IgG glycosylation and pain. We used a cohort of twins from 
TwinsUK registry with established phenotypes of LBP and using a recently developed high-throughput analysis 
method quantified IgG glycans in their plasma specimens. After pre-processing and filtering of the data, a total 
of 4511 individuals were analyzed including 1215 pairs of DZ twins, 491 pairs of MZ twins, and 1099 unpaired 
individuals (Table 1). Low back pain status was known for 3557 individuals.
Analysis of association between glycan levels and LBP. Overall, 76 directly measured or derived gly-
can traits were assessed for an association with LBP (Supplementary Table 1). Linear mixed model analysis with 
BMI, sex, inflammatory diseases and LBP status included as fixed covariate and variation in IgG glycan quantities 
within twin pairs as random effect revealed nominally statistically significant associations of LBP with several 
glycan traits with the strongest association seen for IGP49 (GP10n) (Fig. 1). However, none of the associations 
passed the significance threshold set to control for multiple testing (p = 0.0027). Same was true for the analysis 
of correlations between glycan levels and summary scores for lumbar magnetic resonance imaging signs (LSUM; 
Supplementary Table 2; Supplementary Figure 1).
Trait Value %
Age ± SD 51.8 ± 14.1 –
Females/males 4175/336 92.6/7.4
BMI ± SD 26.3 ± 5.0 –








unknown in at least 





unknown in at least 
one of the twins
146/452/316/301 12.0/37.2/26.0/24.8
Table 1.  Demographics of the studied twins.
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WGCNA. Using the weighted correlation network analysis (WGCNA) methodology, we carried out a network 
analysis for glycan levels to establish clusters of correlated glycans which, possibly, reflect their functional rela-
tionships and revealed associations between these clusters and pain phenotypes.
Using signed networks, we identified seven modules of correlated glycans (Fig. 2; Supplementary Table 1), 
which can be grouped into two big branches comprising yellow, brown and turquoise modules, from one hand, 
and black, green, blue and red modules, from the other hand (Fig. 3).
The most abundand turquoise module is comprised of glycans with bisecting N-acetylglucosamine (GlcNAc) 
which was reported to promote antibody-dependant cell-mediated cytotoxicity (ADCC)22. Similarly, the brown 
module belonging to the same branch of modules, contains non-fucosylated glycans, which also promote ADCC. 
The yellow module from the same branch is enriched of bi-galactosylated and sialylated glycans which are main 
immunosuppressive glycans.
Another branch’s biggest blue module, in opposition to the turquoise and brown modules, is enriched of 
fucosylated glycans, does not include glycans with bisecting GlcNAc, and also contains some monogalactosylated 
glycans. The red module is comprised of primarily disialyated glycans exhibiting immunosupressive capacity. 
The green module is mostly presented by minor structures, beside GP4, IGP43 (GP4n) and IGP55 (G0n), which 
are main non-galactosylated glycans exhibiting pro-inflammatory features. Finally, the black module contains 
glycans with one sialic acid, bisecting GlcNAc, and core fucose.
To reveal relationships between glycan modules and pain phenotypes, we carried out a correlation analysis 
between module eigenvalues (estimated as first principal component of glycan levels in a module) and LBP and 
MRI trait LSUM (Fig. 4). LBP was found to be positively correlated with turquoise and brown modules and neg-
atively with blue module. A hint to correlation between green module and LBP was seen; however, these correla-
tions did not reach statistical significance.
Also, even though the correlation strength between glycan modules and MRI-traits was of similar magnitude 
as those for LBP (R = 0.04–0.05), the correlations did not reach statistical significance for MRI-traits.
Figure 1. P-values (−log10) for the analysis of associations between glycan levels and low back pain. Linear 
mixed models were used to estimate the associations using LBP status, BMI, sex, and major inflammatory 
disease status as fixed factors and family status as a random factor.
Figure 2. Modules of correlated glycans obtained using WGCNA methodology. 
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Average glycan significance for this phenotype (defined as the average for the correlation coefficients between 
glycan levels in a module and a trait) was highest for blue and turquoise modules for LBP (Fig. 5). These results 
suggest that glycans from the blue and turquoise modules may be of especial interest for subsequent study of their 
relationships with pain phenotype.
Discordant twins analysis. To further analyse the relationships between glycome and pain phenotypes, we 
carried out comparisons of glycan levels in MZ and DZ twins discordant for LBP using paired t-test.
For MZ twins, we identified statistically significant differences between the twins with and without LBP for the 
IGP65 (FG2n/G2n), IGP74 (FBG2n/FG2n), IGP75 (FBG2n /[FG2n + FBG2n ]), and IGP76 (FG2n/[BG2n + FBG2n]) 
Figure 3. Relationships between modules of correlated glycans. 
Figure 4. Correlations between module eigenvalues and pain phenotypes. Correlations were calculated 
between module eigenvalues (vector of first principal component of glycans in a module) and low back pain 
(LBP) using point-biserial correlation coefficient and summary score for magnetic resonance imaging signs for 
lumbar spine (LSUM) using Pearson correlation coefficients. Corresponding p-values are provided in brackets.
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derived traits (Fig. 6; p < 0.0027). Notably, these four glycan traits belong to the blue and turquoise modules 
identified in the WGCNA analysis. Accordingly, IGP65 and IGP76 of the blue module were found to be elevated 
in MZ twins without LBP, while IGP74 and IGP75 of the turquoise module were elevated in MZ twins with LBP 
(Fig. 7). The four glycan traits were derived from neutral glycans GP14 and GP15, and also GP13 for IGP76, with 
GP14 being the numerator for IGP65 and IGP76, while GP15 the numerator for the other two (Supplementary 
Table 1). Intriguingly, neither GP14, nor GP15 showed any trend to association with LBP; however, there was 
a weak, but significant negative correlation between GP14 and LCUM values (Pearson r = −0.08, p = 0.04; 
Supplementary Table 2; Supplementary Figure 1).
No statistical significant differences in glycan levels were found for DZ twins or MZ and DZ twins combined.
To pursue a cause for association between LBP and glycan levels in MZ twins discordant for LBP, we split them 
into groups of high and low level of IGP65, IGP74, IGP75, and IGP76 using 25% and 75% quintiles as the cut off 
points and compared the prevalence of systemic inflammatory disorders (rheumatoid arthritis, systemic lupus 
erythematosus, ulcerative colitis and Crohn’s disease) in these groups. We found the increase of inflammatory 
diseases in individuals exhibiting low levels of IGP65 and IGP76 and high levels of IGP74 and IGP75 (Fig. 8). This 
pattern was in full agreement with the observation of association between these glycan levels and LBP, though 
the differences in inflammatory disorders prevalence did not reach statistical significance (according to Fisher’s 
exact test p-values).
Figure 5. Average glycan significance across modules for LBP. Glycan significance was defined as the average 
coefficient of correlation between a trait and glycan levels in a module; p-value is given for Kruskal-Wallis test 
for the difference of glycan significance across the modules.
Figure 6. P-values (−log10) for comparisons of mean glycan levels in MZ twins discordant for LBP 
phenotype by paired t-test. Red line corresponds to p = 0.0027 which was taken as the significance threshold 
based on the 19 effective independent tests with Sidak’s correction for multiple testing.
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Discussion
In this study we have evaluated association between levels of plasma IgG glycans and 
LBP. Linear mixed-models analysis did not reveal statistically significant (p < 0.0027) associations between 
glycan levels and LBP. However, for several glycans nominally significant associations were obtained.
In an attempt to consider glycome as a whole, we carried out a network analysis using weighted correlation 
network approach (WGCNA). This is a powerful methodology for revealing clusters (modules) of multiple omic 
traits, such as genome-wide gene expression or global methylation profiles, and placing them into a biological 
context through the analysis of associations between the clusters and diseases or traits of interest23–28. To the best 
of our knowledge, this method has never been applied before to glycome. Even though, glycans do not interact 
with each other in a way of genes or proteins, the network methodology underlying WGCNA analysis still seems 
valuable for glycome as it allows revealing functionally related groups of glycans exhibiting overlapping biological 
activity.
Using WGCNA approach we revealed seven modules of glycans clustered according to their functional capa-
bilities, with the two biggest modules (turquoise and blue) enriched with glycans with opposite potential for 
the development of ADCC through the regulation of core fucosylation and bisection. Fucosylation is crucial 
in many biological processes and inflammation in particular. On average, 95% of the IgG population is core 
Figure 7. Glycan levels in MZ twins discordant for LBP phenotype. 
Figure 8. The prevalence of systemic inflammatory disorders (rheumatoid arthritis, systemic lupus 
erythematosus, ulcerative colitis, and Crohn’s disease) in twins with high and low levels of glycans and 
discordant for LBP. The cut off points for glycans levels were set at 25% and 75% quintile for the corresponding 
distribution.
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fucosylated29; core fucose prevents activation of ADCC, thus, most of the immunoglobulins have a “safety 
switch”, which prevents them from killing the target cell. Malfunction of this system appears to be associated 
with autoimmune diseases, as indicated by both pleiotropic effects of genes that associate with IgG glycosylation 
on different inflammatory and autoimmune diseases, and observed alterations in IgG glycosylation in systemic 
lupus erythematous30,31 and many inflammatory diseases32. We observed a positive correlation between LBP and 
“pro-ADCC” turquoise and brown modules and a negative correlation between LBP and “anti-ADCC” blue mod-
ule (Fig. 4). Assuming that the development of LBP syndrome is in part related to inflammation33 and that ADCC 
contributes to the joint inflammation in some types of back pain34, one could expect that the decreased levels of 
core fucosylation and increased levels of bisecting GlcNAc in IgG glycans may contribute to increased ADCC 
and inflammation in LBP patiens. This observation corroborates with the finding of the significant difference 
in the levels of blue and turquoise module glycans in MZ twins discordant for LBP: IGP65 and IGP76 (blue 
module) were decreased in LBP-positive persons, while IGP74 and IGP75 (turquoise module) were increased 
in LBP-positive persons (Figs 6 and 7). Accordingly, we found the increased prevalence of major inflammatory 
diseases in LBP-discordant MZ twins with low levels of IGP65 and IGP76 and high levels of IGP75 and IGP76 
(Fig. 8). Even though, the differences in the diseases prevalence were not statistically significant, the pattern of 
the differences corresponds to the pattern of association between the glycan levels and LBP, thus linking the three 
entities (glycans, LBP, and systemic inflammatory diseases). It is worth noting, that during inflammation process 
IgG glycome may vary in a quite complex way following several different patterns35. Therefore, the relationships 
between fucosylation, bisecting GlcNAc and LBP may not be entirely straightforward.
Interestingly, no statistically significant differences were found between DZ twins discordant for LBP. This may 
reflect a pronounced impact of environmental or gene-environment variability on co-variation between glycan 
levels and LBP.
Conclusion
The current study was a first attempt to establish relationships between LBP and glycome. We proceeded from 
a hypothesis that LBP may be associated with an occult inflammation reflected by IgG glycan levels. We found 
consistent associations between pro- and anti-ADCC glycans with LBP, thus providing a proof for the tested 
hypothesis. Overall, our findings provide a further clue how inter-individual differences in IgG glycosylation 
might affect mechanisms of the development of LBP and suggest that glycans can be of interest as possible patient 
stratification biomarkers of this pain syndrome.
Material and Methods
Sample. Participants were a sample of MZ and DZ twins enlisted in the Twins UK registry36. The partici-
pants in the present study had undergone height and weight measurements used to calculate BMI. Collection of 
socio-demographic and LBP data was carried out during clinical visit or via a postal self-completion question-
naire. The twins were unaware of the precise research hypothesis addressed in the present study.
The study was carried out under the auspices of the FP7 PainOmics project and was approved by the St 
Thomas’ Hospital Research Ethics Committee. All the methods were carried out in accordance with the approved 
guidelines. All participating twins provided signed informed consent.
Participating twins underwent an assessment that included a nurse-led interview and a number of clinical 
and laboratory tests. As part of the study, the twins completed two standardized questionnaires relating to their 
lifetime history of low back symptoms. The questionnaires have been completed by each twin separately. The 
questionnaires included written questions and a mannequin pain diagram allowing an assessment of the timing, 
distribution, radiation, severity, and duration of pain together with information relating to functional disability. 
Low back pain was defined on a mannequin as being located between the 12th rib and the gluteal folds. First 
questionnaire followed the format of questions used in the UK Medical Research Council Nurses Study37 and the 
procedure of the assessment is detailed elsewhere38. The assessment of twins using this questionnaire was done in 
framework of the UK Twin Spine Study7,39. Another questionnaire followed the format of London Fibromyalgia 
Epidemiology Symptom Screening Questionnaire40. Specifically, the following questions have been used: “In the 
past month, have you had pain symptoms in this area (central lumbar region, left lumbar region, right lumbar 
region, left buttock, right buttock) lasting at least 24 hours? ” and “Have you had pain like this in this areas for at 
least the past 3 months? ”. This assessment using this questionnaire was done in framework of ongoing studies of 
chronic pain syndromes undertaken by the Department of Twin Research and Genetic Epidemiology at King’s 
College London41.
The LBP phenotype was defined as a binary trait based on questionnaire responses (1 = affected and 0 = non-
affected). Participants were categorised as cases for LBP if they reported having the syndrome with a total dura-
tion of >1 month and associated with disability according to the first questionnaire or at least 3 months according 
to the second questionnaire. Overall, 1656 and 2975 partly overlapping participants have been assessed using first 
and second questionnaire, respectively, which allowed identification of the LBP status in 3557 participants. Out 
of them, 585 participants (35.3% tested using first questionnaire) had disabling LBP lasting >1 month and 582 
participants (20.0% tested using second questionnaire) had LBP lasting at least 3 months.
For 647 participants magnetic resonance imaging (MRI) was carried out as a part of LBP status assessment. 
The MRI scan was performed using a Siemens (Munich, Germany) 1.0 T superconducting magnet. Sagittal images 
were obtained using a fast spin-echo sequence of time to recovery (TR)/time to echo (TE) 5000–4500/112 msec, 
with a slice thickness of 4 mm. Grading was performed on T2-weighted images, although T1 images were also 
obtained for certain measurements. Axial sections were obtained at selected levels to assess structural changes in 
individuals who had features suggesting prolapse. To avoid problems related to diurnal variation in disc height all 
MRI scans were performed >1 hour after the subjects arose from sleep in the morning, with no exercise or other 
rest allowed between arising and the scan, and importantly, each twin pair was scanned at the same appointment 
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and on the same machine42. A disease (LBP) severity score was constructed from the sum of scores for disc bulge, 
height, signal change, and narrowing in the lumbar spine (LSUM).
Analysis of IgG glycans
Isolation of IgG from Human Plasma. The IgG was isolated using protein G monolithic plates (BIA 
Separations, Ajdovščina, Slovenia) as described previously29. Briefly, 50 to 90 μL of serum was diluted 7 × with 
1 × PBS, pH 7.4, applied to the protein G plate and instantly washed with 1 × PBS, pH 7.4, to remove unbound 
proteins. IgG was eluted with 1 mL of 0.1 M formic acid (Merck, Darmstadt, Germany) and neutralized with 1 M 
ammonium bicarbonate (Merck).
Glycan Release and Labeling. IgG samples were first denatured with addition of 30 μL 1.33% sodium 
dodecyl sulfate (w/v) (Invitrogen, Carlsbad, CA) and by incubation at 65 °C for 10 min. Subsequently, 
10 μL of 4% Igepal-CA630 (Sigma-Aldrich, St. Louis, MO) and 1.25 mU of PNGase F (ProZyme) in 10 μL 
5 × phosphate-buffered saline were added to the samples. The samples were incubated overnight at 37 °C for 
N-glycan release. The released N-glycans were labeled with 2-AB. The labeling mixture was freshly prepared by 
dissolving 2-AB (Sigma–Aldrich) in dimethyl sulfoxide (Sigma–Aldrich) and glacial acetic acid (Merck) mix-
ture (85:15, v/v) to a final concentration of 48 mg/mL. A volume of 25 μL of labeling mixture was added to each 
N-glycan sample in the 96-well plate. Also, 25 μL of freshly prepared reducing agent solution (106.96 mg/mL 
2-picoline borane [Sigma-Aldrich] in dimethyl sulfoxide) was added and the plate was sealed using adhesive 
tape. Mixing was achieved by shaking for 10 min, followed by 2-hour incubation at 65 °C. Samples (in a volume 
of 100 μL) were brought to 80% acetonitrile (ACN) (v/v) by adding 400 μL of ACN (J.T. Baker, Phillipsburg, NJ). 
Free label and reducing agent were removed from the samples using hydrophilic interaction chromatography–
solid-phase extraction. An amount of 200 μL of 0.1 g/mL suspension of microcrystalline cellulose (Merck) in 
water was applied to each well of a 0.45 μm GHP filter plate (Pall Corporation, Ann Arbor, MI). Solvent was 
removed by application of vacuum using a vacuum manifold (Millipore Corporation, Billerica, MA). All wells 
were prewashed using 5 × 200 μL water, followed by equilibration using 3 × 200 μL acetonitrile/water (80:20, v/v). 
The samples were loaded to the wells. The wells were subsequently washed seven times using 200 μL acetonitrile/
water (80:20, v/v). Glycans were eluted two times with 100 μL of water and combined eluates were stored at 
−20 °C until usage.
Hydrophil ic  Interaction Chromatography (HILIC)–Ultra Performance Liquid 
Chromatography. Fluorescently labeled N-glycans were separated by hydrophilic interaction chromatogra-
phy on a Waters Acquity ultra performance liquid chromatography (UPLC) instrument (Milford, MA) consisting 
of a quaternary solvent manager, sample manager, and an FLR fluorescence detector set with excitation and emis-
sion wavelengths of 250 and 428 nm, respectively. The instrument was under the control of Empower 2 software, 
build 2145 (Waters). Labeled N-glycans were separated on a Waters bridged ethylene hybrid, glycan chromatogra-
phy column, 100 × 2.1 mm internal diameter, 1.7-μm bridged ethylene hybrid particles, with 100 mM ammonium 
formate, pH 4.4, as solvent A and acetonitrile as solvent B. The separation method used a linear gradient of 75% 
to 62% acetonitrile (vol/vol) at flow rate of 0.4 mL/min in a 25-minute analytical run. Samples were maintained 
at 5 °C before injection, and the separation temperature was 60 °C. The system was calibrated using an external 
standard of hydrolyzed and 2-AB labeled glucose oligomers from which the retention times for the individual 
glycans were converted to glucose units. Data processing was performed using an automatic processing method 
with a traditional integration algorithm after which each chromatogram was manually corrected to maintain the 
same intervals of integration for all the samples. The chromatograms were all separated in the same manner into 
24 peaks (GP1-GP24).
Statistical analysis. Pre-processing and filtering. Directly measured glycan levels were normalized and 
experimental noise was removed through filtering and batch correction. Before this, we removed GP3 and com-
bined GP20 and GP21 into a single trait.
First, we filtered out most extreme values from the dataset (beyond 0.999% percentile). Then, quotient nor-
malization was applied using median values across the dataset as a reference43. Batch effect associated with dif-
ferent plates used to measure glycan levels was identified and corrected for using ratio-based method with either 
geometric mean or median44. As the results were almost equivalent, herewith, we report only the results for the 
dataset corrected with geometric mean.
After these steps, we estimated 55 derived glycan levels from the directly measured glycans45 using glycanr 
package for R [https://github.com/iugrina/glycanr] (Supplementary Table 1). These derived traits average par-
ticular glycosylation features (galactosylation, fucosylation, sialylation) across different individual glycan struc-
tures and consequently they are more closely related to individual enzymatic activities and underlying genetic 
polymorphisms. Finally, we applied inverse transformation of ranks to normality to obtain standard Normal 
distribution using rntransform function from GenABEL package for R46.
After pre-processing we assessed the dependency between the glycan traits and such confounders as age, 
sex, and body-mass index (BMI). For age piece-wise relationships with glycan levels were found, which made it 
unjustified adding age in linear regression models as a confounder. Therefore, before further analysis we corrected 
glycan levels for age (through residuals) by segmented regression using 40–45 years as initial break-down 
points as implemented in segmented package for R47. The choice of the break-down points was done based on 
the observation of the correlation clouds for age and glycans followed by a bootstrap based search for “true” 
breakpoints. Depending on specific glycans, both BMI and sex exhibited remarkable (and significant) to negligible 
(and insignificant) linear relationships with glycan levels.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:26815 | DOI: 10.1038/srep26815
Linear mixed-models analysis. Because of the twin structure of the dataset, association analyses between disease 
status and glycan traits were performed using linear mixed models with lme4 package for R with BMI and sex 
included as fixed covariates and variation in IgG glycan quantities between twin pairs as random effect. Also, for 
36 participants a diagnosis of a major systemic inflammatory disorder was established, including rheumatoid 
arthritis, systemic lupus erythematosus, ulcerative colitis, and Crohn’s disease. As people with such diagnoses 
normally undergo therapy with painkillers and anti-inflammatory medicine, and also the diseases have previously 
been found associated with variation in glycan levels, we included the diseases status as a fixed effect covariate in 
the analysis. The association was analysed for each glycan separately.
Weighted glycan “expression” networks. We used WGCNA package for R48,49 to carry out an exploratory analysis 
of “network” dependencies between the glycan traits. The algorithm of the analysis is based on the estimation of 
correlations between the glycan levels across the dataset followed by extraction of relatively independent modules 
of correlated glycans. Glycan levels were adjusted for age, sex, BMI, and inflammatory disease status before the 
analysis. Signed networks algorithm was used which takes into account the direction of the correlation between 
glycans. The modules (represented by their eigenvalue estimated as first principal component for the glycans in 
every module) then were correlated with the pain phenotypes, including LBP and MRI trait LSUM. To estimate 
correlations between glycan modules and pain phenotypes we used point-biserial correlation coefficients and 
Pearson’s correlation coefficients for qualitative and quantitative traits, respectively.
Discordant twins analysis. We compared the glycan levels in MZ and DZ twins discordant for LBP using paired 
t-test. Prior to the test, glycan levels were adjusted for age, sex, BMI, and inflammatory disease status.
The significance level consideration. There is an essential correlation between the glycan traits, many of which 
were derived from the original set of directly measured glycans. This complicates straightforward application of 
correction for multiple testing due to the violation of the requirement for the independence of the tests. Taking 
this into account, we estimated the effective number of independent statistical tests as of 1950, which after Sidak’s 
correction for multiple testing provided the significance level of 0.0027.
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